ImmunoPrecise Antibodies Ltd. (IPA)
NASDAQ: IPA · Real-Time Price · USD
0.3800
-0.0120 (-3.06%)
Mar 31, 2025, 3:41 PM EDT - Market open
ImmunoPrecise Antibodies Employees
As of April 30, 2024, ImmunoPrecise Antibodies had 101 total employees, including 72 full-time and 29 part-time employees. The number of employees decreased by 1 or -0.98% compared to the previous year.
Employees
101
Change (1Y)
-1
Growth (1Y)
-0.98%
Revenue / Employee
$164,169
Profits / Employee
-$319,781
Market Cap
17.39M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Apr 30, 2024 | 101 | -1 | -0.98% |
| Apr 30, 2023 | 102 | 17 | 20.00% |
| Apr 30, 2022 | 85 | 12 | 16.44% |
| Apr 30, 2021 | 73 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
IPA News
- 3 days ago - ImmunoPrecise Antibodies Ltd. (IPA) Q3 2025 Earnings Call Transcript - Seeking Alpha
- 3 days ago - ImmunoPrecise Antibodies (IPA) Reports Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 - Business Wire
- 18 days ago - ImmunoPrecise Antibodies and a Global Biotechnology Leader Enter into a USD $8M-$10M Partnership for the Development of Novel Cancer Therapeutics. - Business Wire
- 19 days ago - IPA to Reschedule Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 28, 2025 - Business Wire
- 26 days ago - IPA to Report Financial Results and Recent Business Highlights for Third Quarter Fiscal Year 2025 on March 13, 2025 - Business Wire
- 4 weeks ago - IPA and RIBOPRO Partner to Advance mRNA-Driven Antibody Discovery, Unlocking New Frontiers in Immunotherapy - Business Wire
- 5 weeks ago - ImmunoPrecise Antibodies Announces Key Leadership Changes - Business Wire
- 5 weeks ago - ImmunoPrecise Antibodies Announces Transfer to Nasdaq Capital Market and Extension of Bid Price Compliance Period - Business Wire